Fludarabine

製品コードS1491 別名:FaraA, Fludarabinum

Fludarabine化学構造

分子量(MW):285.23

Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.

サイズ 価格(税別)  
JPY 20932.00
JPY 16102.00
JPY 51460.00
JPY 78020.00
JPY 161020.00

カスタマーフィードバック(4)

  • ERK signaling regulates STAT1 phosphorylation, and pSTAT1 modulates MHC II expression in the spinal cord under BCP conditions. AG490 (5 μg in 10 μL), Fludarabine (10 μg in 10 μL), or U0126 (5 μg in 10 μL) was intrathecally injected into cancer-bearing rats once a day for 14 days, beginning immediately after carcinoma cell inoculation (n = 3 in each group). (A) Representative western blot showing pSTAT1ser727, total STAT1, pERK42/44, total ERK42/44, CIITA, MHC II RTIB, and b actin protein levels in the spinal cords of BCP rats.

    Brain Behav Immun, 2017, 60:161-173. Fludarabine purchased from Selleck.

    Imatinib mesylate (IM) in combination of fludarabine phosphate (F-AMP) significantly inhibits Ki67 and c-KIT expression in GIST-T1 tumor xenografts. Tumors were collected on the day after the last treatment and were then subjected to immunohistochemical detection of Ki67 and c-KIT expression. Representative images of immunohistochemical staining of Ki67 and c-KIT in mice tumors.

    Mol Cancer Ther, 2014, 13(10): 2276-87 . Fludarabine purchased from Selleck.

  • Normal human KC pretreated with STAT1 inhibitor (fludarabine [10 uM]) or STAT3 inhibitor (STA-21 [2 uM]) for 24 h. The mRNA levels of hBD2 and hBD3 were assessed by qRT-PCR.

    Mol Cell Biol 2014 34(24), 4368-78.. Fludarabine purchased from Selleck.

    Bacterial infection in IPEC-J2 cells. The invasion and attachment of EHECO157:H7 was increased in the IPEC-J2 cells in the presence of 10 μM fludarabine. Data are expressed as the mean ± SEM (n= 6). Differences between groups were determined by paired samples t-test. *P<0.05 compared with the control.

    Int Immunopharmacol, 2016, 36:199-204.. Fludarabine purchased from Selleck.

製品安全説明書

STAT阻害剤の選択性比較

生物活性

製品説明 Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.
ターゲット
STAT1 [4]
(Vascular smooth muscle cells)
体外試験

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  NIryZY9HfW6ldHnvckBCe3OjeR?= NEGxWokzOCEQvF2= MoHVNlQhcA>? NGLPUnRqdmirYnn0d{BmgHC{ZYPzbY9vKG:oIFnEUy=> MnrNNlU6PDB5MUK=
MV-4-11 NFPDe2NCeG:ydH;zbZMhSXO|YYm= MmTVNk42KM7:TR?= NFqy[oc1QCCq M1jZeIlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 NIPt[GIzPTFzMUW4Ny=>
THP-1 NHzJSXJCeG:ydH;zbZMhSXO|YYm= MYCyMlUh|ryP M2iwNFQ5KGh? NWHOZXNFcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> NWnSUVdOOjVzMUG1PFM>
MOLM 13 MVLBdI9xfG:|aYOgRZN{[Xl? MlOxNk42KM7:TR?= M1HkblQ5KGh? NHToRnNqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> M{fN[lI2OTFzNUiz
KBM3/Bu2506 MWLBdI9xfG:|aYOgRZN{[Xl? M3vDc|IvPSEQvF2= M1HmelQ5KGh? MoHKbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= NFHrfpEzPTFzMUW4Ny=>
Nalm-6 NX3veWZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFn3S5dKSzVyPUG4JO69VQ>? MnPwNlUxPjFzMEG=
Reh MoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7V[HRKSzVyPUOwJO69VQ>? NXXMOYdNOjVyNkGxNFE>
U2937 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF4IN88US=> MnzSNlUxPjFzMEG=
Mec-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[2TmlEPTExvK61NFAh|ryP MYKyOVA3OTFyMR?=
RPMI-8226 NVnpelJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTVyMDFOwG0> NWexPXdFOjVyNkGxNFE>
Molt-4 M3nrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HnOWlEPTB;MUiwJO69VQ>? MV[yOVA3OTFyMR?=
Nalm-6-FluR NUmwWY1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrnTZlKSzVyPUK1NEDPxE1? NEHBS2wzPTB4MUGwNS=>
Raji  MoLsSpVv[3Srb36gRZN{[Xl? MnHhN:Kh|ryP NFK2W20zPC92OD:3NkBp NULvUlgzcW6mdXPld{Bi[2O3bYXsZZRqd26|IH;mJJA2OyxicE[zJIFv\CCyN{RCpC=> MVSyOFk1ODZ7NR?=
PBMC M2HJWmZ2dmO2aX;uJGF{e2G7 M4jKeFUxNzFyMDFOwG0> NUXnfZZ7OjRiaB?= Mlq4SG1UVw>? M4HPUYlvcGmkaYTzJHNVSVRzIIDoc5NxcG:{eXzheIlwdg>? M4HaS|I1QTFzOEey
MDA-231 NWO3b5l[TnWwY4Tpc44hSXO|YYm= M{O5WlExOCEQvF2= MV2yOEBp NYnTTmgzTE2VTx?= NHXn[HNl\WO{ZXHz[ZMhUUSRIHX4dJJme3Orb36= Mmm3NlQ6OTF6N{K=
624.38mel  NIKwVlFHfW6ldHnvckBCe3OjeR?= MYG1NEDPxE1? NHvo[IEzPCCq NEPLT2VFVVOR NX;UUm1R\GWlcnXhd4V{KEmGTzDlfJBz\XO|aX;u MW[yOFkyOTh5Mh?=
MDA-231 M4HrfGZ2dmO2aX;uJGF{e2G7 MkfxOVAuOjByIN88US=> NXjG[JRHOjRiaB?= NGTIZodFVVOR MYfpcohq[mm2czDJSG8h[WO2aY\peJkhcW6mZYDlcoRmdnSueTDv[kBuWk6DIHzleoVtew>? NXTkPGk{OjR7MUG4O|I>
624.38mel  NWXNdoZlTnWwY4Tpc44hSXO|YYm= M3G1PVUxNTJyMDFOwG0> MVSyOEBp NFzjeZdFVVOR M1fEXIlvcGmkaYTzJGlFVyCjY4Tpeol1gSCrbnTldIVv\GWwdHz5JI9nKG2UTlGgcIV3\Wy| M1vlSlI1QTFzOEey
HMECs NYrNNGFvTnWwY4Tpc44hSXO|YYm= NVzwOYNWOTBywrFOwG3DqA>? MnrtN|bDqGh? MorPbY5pcWKrdIOgTWZP|rQEoHHu[EBNWFNiaX7keYNm\CCVVFHUNUBxcG:|cHjvdplt[XSrb36gZY5lKEmURkGg[ZhxemW|c3nvci=> NED6UogzPDJzMUOyOy=>
HMECs  MoPZSpVv[3Srb36gRZN{[Xl? MUOxNFDDqM7:TdMg Mm\PN|bDqGh? MVLpcohq[mm2czDJSm7PucLibXXkbYF1\WRicHjvd5Bpd3K7bHH0bY9vKG:oIGPURXQyKGGwZDDTWGFVOyxiYoX0JI5wfCCxZjDTWGFVOg>? NV;hR3N4OjR{MUGzNlc>
BJAB M4PoUGFxd3C2b4Ppd{BCe3OjeR?= NWe5SodwPcLizszN Ml71NlQhcA>? Mnv4bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MVmyOFA2PzF2Nx?=
I-83 NIeyeWtCeG:ydH;zbZMhSXO|YYm= NEC0[no2yqEQvF2= NFzYeXIzPCCq MVPpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVSyOFA2PzF2Nx?=
NALM6 M3r5dGFxd3C2b4Ppd{BCe3OjeR?= NVnkfYZQPcLizszN NXvFPVN4OjRiaB?= NYq5OW0zcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NVy2U3lWOjRyNUexOFc>
DU-145 NVflbGZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOwMVExKM7:Zz;tcC=> M1GxXFQ5KGkEoB?= NUj1eY51cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUjTOlZtOjN5M{S4NVU>
Nalm-6 NVPMW3hCTnWwY4Tpc44hSXO|YYm= NF3x[FgyOMLizszN NUeyTYprOS9{L{SgbC=> MmLDbY5lfWOnczDheZRweGijZ4m= M{\KOVI{PjhzMkKz
Reh MW\GeY5kfGmxbjDBd5NigQ>? MVmxNOKh|ryP NUjUVWRsOS9{L{SgbC=> NX[5fJFFcW6mdXPld{BifXSxcHjh[5k> NVn3b4RTOjN4OEGyNlM>
Nalm-6 NH71U4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\pdFNKSzVyIPMIwFEx6oDLzszN MYKyN|Y5OTJ{Mx?=
Reh NV[zfHh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXYRXZ2UUN3MDFijNwyOOLCid88US=> Mk\FNlM3QDF{MkO=
HEC1A MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXLO2wyODBvNUCwJO69VQ>? NFPrOZozPCCq M{\QN4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MlPZNlM2QTV4OUe=
AN3CA Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPVbnQyODBvNUCwJO69VQ>? M4DocVI1KGh? NXvocXU5cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1exe|I{PTl3Nkm3
HEC50B M4rCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;qWlExOC13MECg{txO MlXxNlQhcA>? NHTiNHlqdmirYnn0d{Bk\WyuIHfyc5d1cCC|bHnnbJRtgQ>? MUWyN|U6PTZ7Nx?=
HEC1A NULWZm5mSXCxcITvd4l{KEG|c3H5 NUjudZNyOjBxMUCwJO69VQ>? NYexNVhYOjRiaB?= M3nCN4lv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWSyN|U6PTZ7Nx?=
AN3CA Mne0RZBweHSxc3nzJGF{e2G7 M4LN[lIxNzFyMDFOwG0> NHzXbIgzPCCq NEPSUIhqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MWeyN|U6PTZ7Nx?=
HEC50B NXXydmpISXCxcITvd4l{KEG|c3H5 NYS1PXVbOjBxMUCwJO69VQ>? MV[yOEBp MW\pcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NFTB[pkzOzV7NU[5Oy=>
EHEB MnnqRZBweHSxc3nzJGF{e2G7 M3\WVFQxKM7:TR?= MnnxNlQhcA>? M1TMd4lv\HWlZYOgZZBweHSxc3nz NFXLTmgzOzR7N{C3OS=>
A549 NEKwW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjue4dyUUN3ME2xOU44yrF{LkigxtVO NX;TdlFJOjN|N{exPVI>
A549 GAPDH-deficient MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTF6LkZCtVIvOyEEtV2= MUCyN|M4PzF7Mh?=
CLL  MlfXRZBweHSxc3nzJGF{e2G7 M4L0[|ExKM7:TdMg NGnQN2kzPC17NjDo MW\pcoR2[2W|IHHwc5B1d3SrYzDj[YxtKGSnYYTo MmX3NlIzODd4OE[=
MEC1 MVjBdI9xfG:|aYOgRZN{[Xl? M4HVO|ExOMLizszN NITUVnA4OiCq NFPYb|JqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 NG\PPVIzOjF|Mkm3Ny=>
U937  NXX2NY94SXCxcITvd4l{KEG|c3H5 MXKwMlgh|ryP MmPtOE01QCCq MYLpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= MUCyNlA4PDdyMB?=
U937  M{[4emFxd3C2b4Ppd{BCe3OjeR?= MX2xJO69VQ>? NFKyVog6PiCq MVTpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NHe1eJYzOjB{M{WyNy=>
Daudi MWTBdI9xfG:|aYOgRZN{[Xl? MkHQNlAh|ryP M2PYNVk3KGh? MnXMbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= NYDtbYZXOjJyMkO1NlM>
J45.01 NWTRfZlmSXCxcITvd4l{KEG|c3H5 NELzOFIyKM7:TR?= M1fBdlk3KGh? NHnt[4tqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> NI\sfWUzOjB{M{WyNy=>
RPMI 8226 NEfTXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HsVGlEPTB;MkWuPeKhyrIEoEOuO{DPxE1? MWGyNVk1QDJ4NB?=
CEM NGnWTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJwNNMgxtHDqDBwNDFOwG0> M1r5eVIyQTR6Mk[0
Raji NX\RdI1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXuXVNjUUN3ME2wMlQ4yqEEsdMgNE4xPCEQvF2= MVuyNVk1QDJ4NB?=
U937 NF3ZXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMkVCpOKyyqByLkC0JO69VQ>? NYG5ZYVbOjF7NEiyOlQ>
K562 NHf3VG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fCNWlEPTB;MD60OOKhyrIEoECuNFUh|ryP NXPhUWVROjF7NEiyOlQ>
NALM-6 M3TvVmFxd3C2b4Ppd{BCe3OjeR?= NVL3SIhEOTBizszNxsA> MVWyOEBp Mnj0bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|bHnnbJRtgQ>? MX[yNVY6QTN6Mx?=
JMV-3 NHm0e45CeG:ydH;zbZMhSXO|YYm= MnPpNVAh|ryPwrC= MoLmNlQhcA>? M3TuS4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3zp[4h1dHl? NX\pboNlOjF4OUmzPFM>
EHEB M1;TWmZ2dmO2aX;uJGF{e2G7 M{PmVFUuPTBizszN NFnQc|UzPCCq MmH1[IVkemWjc3XzJJAzOSCneIDy[ZN{cW:wIIPp[45q\mmlYX70cJk> M3\C[lIyOTZ6M{mx
JVM-2  NVrJVVB4TnWwY4Tpc44hSXO|YYm= MWizNEDPxE1? NHniVIgzPCCq NHPU[nll\WO{ZXHz[ZMheDJzIHX4dJJme3Orb36= Ml7TNlEyPjh|OUG=
KBM3/Bu2506 NYPWXYtRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDxTWMzOD1yLk[3JOK2VQ>? NWjGSXNxOjB7M{O1NFk>
KBM3/Bu2506 M1[wSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknoNE43KM7:TR?= MUiyOEBp NGTJcWdqdmO{ZXHz[ZMhfGinIHPlcIwh\nKjY4Tpc44hcW5iUz3wbIF{\Q>? NWD3e4pWOjB7M{O1NFk>
MDA-MB-231 NFjXclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfadGRKSzVyPUSuNEDPxE1? NVPVXpAyOjB2NEezPVA>
MCF-7 NVH4[5VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTvOXJqUUN3ME2xOU4xKM7:TR?= NX3WeWsxOjB2NEezPVA>
HLE-B3  MmTRSpVv[3Srb36gRZN{[Xl? NWLpdoRmOjVizszN Ml[yOFghcA>? MXjicI9kc3NiSV\OMe6{6oDVaX7keYNm\CCVVFHUNUBxcG:|cHjvdplt[XSrb36gZY5lKEmGTzDlfJBz\XO|aX;u NGDqTVYzODR|NUG1PC=>
K562 NXfweW5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1W1N|czKGh? NVrVZ3NQUUN3ME2zMlMhdk1? NGnNV|QzODNyN{G5PC=>
BW-225 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|IxRTFwM{egx7cyOOLKkklCpO69VcLi MUOxPFY3OTN6MB?=
OH-65 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|IxRTFwM{egx7cyOOLKkklCpO69VcLi Ml;PNVg3PjF|OEC=
GR-145 NUno[m1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHsRWNRUUN{ME2yMlc1KMPZIEGw5qiTQCBizszNxsA> NFPnT4QyQDZ4MUO4NC=>
A549 NITy[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jKeGlEOjB;NT60PEDEnyBzMPMIllgh|ryPwrC= NYL0b24zOTh4NkGzPFA>
CaSki  NHnvfFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|IxRTFwM{egx7chOTEkiKK3JO69VcLi NEjE[o0yQDZ4MUO4NC=>
ZMK-1 MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fnT2lEOjB;MT6zO{DEnyBzMPMIllYh|ryPwrC= NITxeHIyQDZ4MUO4NC=>
SKW6.4 MU\BdI9xfG:|aYOgRZN{[Xl? M37rWFAvODFvMUCg{txO NWjoT3pNOjRxNEigbC=> MV\pcoR2[2W|IHPlcIwh\GWjdHigbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? NWDlS3duOThyOUKzOFA>
RPMI 8226 NV;4eWtlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWyOEBp NILm[WVKSzVyPUGuOVTDqM7:TR?= M2H6fFE4QTd4MUi2
MM.1S MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTJT441QCCq NFfGWYtKSzVyPUGzMlQ5yqEQvF2= NYXsN4pnOTd7N{[xPFY>
MM.1R MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4izUFQ5KGh? MV\JR|UxRTN|Lke5JO69VQ>? NILJd4kyPzl5NkG4Oi=>
U937 NYHIToZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTYTWM2OD1|LEKwNEDDuSB3NkCgcm0> NXnKVGZtOTV7M{CzOlE>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • 濃度: 2 μg/mL
  • 反応時間: 24 hours
  • 実験の流れ:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • 製剤: PBS
  • 投薬量: 40 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
体内 左から右までの手順で、溶剤を製品に加えることです:
30% propylene glycol, 5% Tween 80, 65% D5W
いい結果が出るために、混じった後、直ちに使うと推めます。
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 285.23
化学式

C10H12FN5O4

CAS No. 21679-14-1
保管
別名 FaraA, Fludarabinum

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01585415 Terminated Metastatic Cancer|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 9, 2012 Phase 1
NCT01503242 Recruiting Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) January 9, 2012 Phase 1
NCT01319565 Active, not recruiting Metastatic Melanoma|Skin Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 9, 2011 Phase 2
NCT01145209 Active, not recruiting Small Lymphocytic Lymphoma|CLL (Chronic Lymphocytic Leukemia) National Heart, Lung, and Blood Institute (NHLBI)|University of Virginia|GlasoSmithKline|National Institutes of Health Clinical Center (CC) June 9, 2010 Phase 2
NCT02500576 Recruiting Melanoma M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.|Prometheus Inc. August 7, 2015 Phase 2
NCT01174121 Recruiting Metastatic Colorectal Cancer|Metastatic Gastric Cancer|Metastatic Pancreatic Cancer|Metastatic Hepatocellular Carcinoma|Metastatic Cholangiocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2010 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • 回答:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

Related Antibodies

STATシグナル伝達経路

相関STAT製品

Tags: Fludarabineを買う | Fludarabine ic50 | Fludarabine供給者 | Fludarabineを購入する | Fludarabine費用 | Fludarabine生産者 | オーダーFludarabine | Fludarabine化学構造 | Fludarabine分子量 | Fludarabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID